Integrated Diagnostics Holdings PLC
LSE:IDHC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.2845
0.535
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Integrated Diagnostics Holdings PLC
Integrated Diagnostics Holdings PLC
Cost of Revenue
Integrated Diagnostics Holdings PLC
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Integrated Diagnostics Holdings PLC
LSE:IDHC
|
Cost of Revenue
-egp3B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
Integrated Diagnostics Holdings PLC
Glance View
Integrated Diagnostics Holdings Plc engages in the provision of diagnostics services including pathology and molecular diagnostics, genetics testing and basic radiology to patients and other laboratories. The firm operates in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The company is engaged in offering services in immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology and radiology. Its brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan), and Echo-Lab (Nigeria). The company operates in approximately 507 branches. IDH offers 2,000 diagnostic pathology tests ranging from routine to advanced. Its common tests include those for cholesterol, diabetes, pregnancy, and substance abuse. Through Al Borg Scan, it offers a range of radiology services, including but not limited to magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, x-ray, mammograms, cath lab facilities, and positron emission tomography-computed tomography (PET-CT).
See Also
What is Integrated Diagnostics Holdings PLC's Cost of Revenue?
Cost of Revenue
-3B
EGP
Based on the financial report for Jun 30, 2024, Integrated Diagnostics Holdings PLC's Cost of Revenue amounts to -3B EGP.
What is Integrated Diagnostics Holdings PLC's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-22%
Over the last year, the Cost of Revenue growth was -32%. The average annual Cost of Revenue growth rates for Integrated Diagnostics Holdings PLC have been -31% over the past three years , -22% over the past five years .
You don't have any saved screeners yet
